Health
CureVac starts clinical trial for COVID-19 vaccine candidate – Reuters India
German biotech firm CureVac has enrolled the first participant for a Phase 2b/3 clinical trial of its COVID-19 vaccine candidate, it said on Monday.
By Reuters Staff
FILE PHOTO: A vaccination against the coronavirus disease (COVID-19) from German biotechnology company CureVac is ready to use at the start of a clinical test series in the tropical institute of the university clinic in Tuebingen, Germany, June 22, 2020. REUTERS/Kai Pfaffenbach
BERLIN (Reuters) -German biotech firm CureVac has enrolled the first participant for a Phase 2b/3 clinical trial of its COVID-19 vaccine candidate, it said on Monday.
The trial, which is relevant for regulatory…
-
Business19 hours agoBroker names 2 small cap ASX shares to buy for big returns
-
Noosa News18 hours agoMin Woo Lee, Adam Scott and Cameron Smith in the mix after Australian PGA opening round in Brisbane
-
Business18 hours agoThese top ASX 200 stocks could rise 25% to 60%
-
Noosa News22 hours agoEverything To Know About Spilt Milk 2025